238 related articles for article (PubMed ID: 29210637)
21. Recent researches in metal supramolecular complexes as anticancer agents.
Zhou CH; Zhang YY; Yan CY; Wan K; Gan LL; Shi Y
Anticancer Agents Med Chem; 2010 Jun; 10(5):371-95. PubMed ID: 20380632
[TBL] [Abstract][Full Text] [Related]
22. New applications of old metal-binding drugs in the treatment of human cancer.
Schmitt SM; Frezza M; Dou QP
Front Biosci (Schol Ed); 2012 Jan; 4(1):375-91. PubMed ID: 22202066
[TBL] [Abstract][Full Text] [Related]
23. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
24. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy.
Liu J; Lai H; Xiong Z; Chen B; Chen T
Chem Commun (Camb); 2019 Aug; 55(67):9904-9914. PubMed ID: 31360938
[TBL] [Abstract][Full Text] [Related]
25. Molybdenum Metallopharmaceuticals Candidate Compounds - The "Renaissance" of Molybdenum Metallodrugs?
Jurowska A; Jurowski K; Szklarzewicz J; Buszewski B; Kalenik T; Piekoszewski W
Curr Med Chem; 2016; 23(29):3322-3342. PubMed ID: 27142289
[TBL] [Abstract][Full Text] [Related]
26. Multi-Target Metal-Based Anticancer Agents.
Chen ZF; Orvig C; Liang H
Curr Top Med Chem; 2017 Nov; 17(28):3131-3145. PubMed ID: 28982336
[TBL] [Abstract][Full Text] [Related]
27. Specific interactions of Bi(III) with the Cys-Xaa-Cys unit of a peptide sequence.
Rowinska-Zyrek M; Valensin D; Szyrwiel L; Grzonka Z; Kozlowski H
Dalton Trans; 2009 Nov; (42):9131-40. PubMed ID: 20449188
[TBL] [Abstract][Full Text] [Related]
28. Coordination modes of bidentate lornoxicam drug with some transition metal ions. Synthesis, characterization and in vitro antimicrobial and antibreastic cancer activity studies.
Mahmoud WH; Mohamed GG; El-Dessouky MM
Spectrochim Acta A Mol Biomol Spectrosc; 2014 Mar; 122():598-608. PubMed ID: 24334061
[TBL] [Abstract][Full Text] [Related]
29. Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents.
Pal M; Nandi U; Mukherjee D
Eur J Med Chem; 2018 Apr; 150():419-445. PubMed ID: 29547831
[TBL] [Abstract][Full Text] [Related]
30. Metal-based compounds containing selenium: An appealing approach towards novel therapeutic drugs with anticancer and antimicrobial effects.
Ramos-Inza S; Plano D; Sanmartín C
Eur J Med Chem; 2022 Dec; 244():114834. PubMed ID: 36215861
[TBL] [Abstract][Full Text] [Related]
31. Studies on antimicrobial effects of four ligands and their transition metal complexes with 8-mercaptoquinoline and pyridine terminal groups.
Zhang LJ; Zhang JA; Zou XZ; Liu YJ; Li N; Zhang ZJ; Li Y
Bioorg Med Chem Lett; 2015 Apr; 25(8):1778-1781. PubMed ID: 25791454
[TBL] [Abstract][Full Text] [Related]
32. Future potential of osmium complexes as anticancer drug candidates, photosensitizers and organelle-targeted probes.
Zhang P; Huang H
Dalton Trans; 2018 Oct; 47(42):14841-14854. PubMed ID: 30325378
[TBL] [Abstract][Full Text] [Related]
33. Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.
Silva Dde O
Anticancer Agents Med Chem; 2010 May; 10(4):312-23. PubMed ID: 20380636
[TBL] [Abstract][Full Text] [Related]
34. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.
Paterson BM; Donnelly PS
Chem Soc Rev; 2011 May; 40(5):3005-18. PubMed ID: 21409228
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, spectral, DFT modeling, cytotoxicity and microbial studies of novel Zr(IV), Ce(IV) and U(VI) piroxicam complexes.
El-Shwiniy WH; Zordok WA
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Jun; 199():290-300. PubMed ID: 29627613
[TBL] [Abstract][Full Text] [Related]
36. Advances in cobalt complexes as anticancer agents.
Munteanu CR; Suntharalingam K
Dalton Trans; 2015 Aug; 44(31):13796-808. PubMed ID: 26148776
[TBL] [Abstract][Full Text] [Related]
37. Copper, gold and silver compounds as potential new anti-tumor metallodrugs.
Tan SJ; Yan YK; Lee PP; Lim KH
Future Med Chem; 2010 Oct; 2(10):1591-608. PubMed ID: 21426151
[TBL] [Abstract][Full Text] [Related]
38. Metal-containing drugs and novel coordination complexes in therapeutic anticancer applications--part II.
Kostova I
Anticancer Agents Med Chem; 2010 Jun; 10(5):352-3. PubMed ID: 20545617
[No Abstract] [Full Text] [Related]
39. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
40. Addressing the gaps in homeostatic mechanisms of copper and copper dithiocarbamate complexes in cancer therapy: a shift from classical platinum-drug mechanisms.
Njenga LW; Mbugua SN; Odhiambo RA; Onani MO
Dalton Trans; 2023 May; 52(18):5823-5847. PubMed ID: 37021641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
